메뉴 건너뛰기
Asian Pacific Journal of Cancer Prevention
Volumn 10, Issue 4, 2009, Pages 591-594
Clinico-pathological features and outcomes in chronic phase chronic myeloid leukemia patients treated with hydroxyurea
Author keywords

Chronic myeloid leukemia; Chronic phase; Hydroxyurea; Karachi, Pakistan; Outcome
Indexed keywords

EID: 77951143836     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article
Times cited : (8)
References (16)
  • 1
    • 33845436745 scopus 로고    scopus 로고
    • The myeloproliferative disorders
    • Campbell PJ, Green AR (2006). The myeloproliferative disorders. N Engl J Med, 355, 2452-67.
    • (2006) N Engl J Med , vol.355 , pp. 2452-2467
    • Campbell, P.J.1    Green, A.R.2
  • 2
    • 0017082495 scopus 로고
    • Chemotherapy of blast phase of chronic myeloid leukemia: haplodiploidy and response to therapy
    • Cannelos GP, De Vita VT, Wahang-Peng J (1976). Chemotherapy of blast phase of chronic myeloid leukemia: haplodiploidy and response to therapy. Blood, 47, 1003-9.
    • (1976) Blood , vol.47 , pp. 1003-1009
    • Cannelos, G.P.1    De Vita, V.T.2    Wahang-Peng, J.3
  • 3
    • 0018923095 scopus 로고
    • Combination chemotherapy for terminal phase chronic granulocytic leukemia: Cancer and leukemia group B studies
    • Coleman M, Silver RT, Pajak TF (1980). Combination chemotherapy for terminal phase chronic granulocytic leukemia: Cancer and leukemia group B studies. Blood, 55, 29-36.
    • (1980) Blood , vol.55 , pp. 29-36
    • Coleman, M.1    Silver, R.T.2    Pajak, T.F.3
  • 4
    • 0029947186 scopus 로고    scopus 로고
    • Effects of a selective inhibitor of the ABL tyrosine kinase on growth of BCR/ABL positive cells
    • Drukar BJ, Thamus S, Buchanger E (1998). Effects of a selective inhibitor of the ABL tyrosine kinase on growth of BCR/ABL positive cells. Nat Med, 2, 561-66.
    • (1998) Nat Med , vol.2 , pp. 561-566
    • Drukar, B.J.1    Thamus, S.2    Buchanger, E.3
  • 5
    • 49449106091 scopus 로고    scopus 로고
    • Chromosome abnormalities in cancer
    • Fröhling S, Döhner H. (2008). Chromosome abnormalities in cancer. N Engl J Med, 359, 722-34.
    • (2008) N Engl J Med , vol.359 , pp. 722-734
    • Fröhling, S.1    Döhner, H.2
  • 6
    • 0027300426 scopus 로고
    • Chronic myeloid leukemia: biology and therapy (meeting report)
    • Gale RP, Goldman JM, Groveel G (1993). Chronic myeloid leukemia: biology and therapy (meeting report). Leukemia, 7, 653-8.
    • (1993) Leukemia , vol.7 , pp. 653-658
    • Gale, R.P.1    Goldman, J.M.2    Groveel, G.3
  • 7
    • 77951103275 scopus 로고    scopus 로고
    • Treatment of chronic myeloid leukemia
    • Goldman JM (1997). Treatment of chronic myeloid leukemia. Blood, 8, 21-9.
    • (1997) Blood , vol.8 , pp. 21-29
    • Goldman, J.M.1
  • 8
    • 0027504040 scopus 로고
    • Choice of pre-transplant treatment and timing of transplant for chronic myelogenous leukemia in chronic phase
    • Goldman JM, Szydio R, Horowitz MM (1993). Choice of pre-transplant treatment and timing of transplant for chronic myelogenous leukemia in chronic phase. Blood, 82, 2235-8.
    • (1993) Blood , vol.82 , pp. 2235-2238
    • Goldman, J.M.1    Szydio, R.2    Horowitz, M.M.3
  • 9
    • 0032480589 scopus 로고    scopus 로고
    • Risk assessment of patients with chronic myeloid leukemia before allogenic blood or marrow transplantation
    • Gratwoh IA, Hermans J, Goldman JM (1998). Risk assessment of patients with chronic myeloid leukemia before allogenic blood or marrow transplantation. Lancet, 352, 1087-92.
    • (1998) Lancet , vol.352 , pp. 1087-1092
    • Gratwoh, I.A.1    Hermans, J.2    Goldman, J.M.3
  • 11
    • 0034489987 scopus 로고    scopus 로고
    • Chronic myeloid leukemia
    • Lee SJ (2000). Chronic myeloid leukemia. Br J Hematol, 111, 993-1009
    • (2000) Br J Hematol , vol.111 , pp. 993-1009
    • Lee, S.J.1
  • 12
    • 0032402142 scopus 로고    scopus 로고
    • Response at three months is a good predictive factor for newly diagnosed chronic myeloid leukemia patients treated with recombinant interferon
    • Mahon F, Faber C, Preyo S (1998). Response at three months is a good predictive factor for newly diagnosed chronic myeloid leukemia patients treated with recombinant interferon. Blood, 92, 4059-65.
    • (1998) Blood , vol.92 , pp. 4059-4065
    • Mahon, F.1    Faber, C.2    Preyo, S.3
  • 13
    • 12944309759 scopus 로고    scopus 로고
    • Unrelated donor marrow transplantation for chronic myelogenous leukemia: One years experience at National marrow donor program
    • McGlave PB, Sh Xu, Won N (2000). Unrelated donor marrow transplantation for chronic myelogenous leukemia: One years experience at National marrow donor program. Blood, 95, 2219-225.
    • (2000) Blood , vol.95 , pp. 2219-2225
    • McGlave, P.B.1    Sh Xu2    Won, N.3
  • 14
    • 0029995607 scopus 로고    scopus 로고
    • The molecular biology of chronic myeloid leukemia
    • Melo JV (1996). The molecular biology of chronic myeloid leukemia. Leukemia, 10, 751-6.
    • (1996) Leukemia , vol.10 , pp. 751-756
    • Melo, J.V.1
  • 15
    • 34447544253 scopus 로고    scopus 로고
    • bcr-abl Tyrosine kinase inhibitors for chronic myelogenous leukemia
    • Schiffer CA (2007). bcr-abl Tyrosine kinase inhibitors for chronic myelogenous leukemia. N Engl J Med, 357, 258-69.
    • (2007) N Engl J Med , vol.357 , pp. 258-269
    • Schiffer, C.A.1
  • 16
    • 0021336851 scopus 로고
    • Prognostic discrimination in "good risk" chronic granulocytic leukemia
    • Sokal JE, Cox EB, Baccmans M (1984). Prognostic discrimination in "good risk" chronic granulocytic leukemia. Blood, 63, 789-99.
    • (1984) Blood , vol.63 , pp. 789-799
    • Sokal, J.E.1    Cox, E.B.2    Baccmans, M.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.